Jin Medical International Ltd.
Jin Medical International Ltd. Fundamental Analysis
Jin Medical International Ltd. (ZJYL) shows moderate financial fundamentals with a PE ratio of 18.67, profit margin of 5.76%, and ROE of 4.14%. The company generates $0.0B in annual revenue with strong year-over-year growth of 18.57%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 49.9/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze ZJYL's fundamental strength across five key dimensions:
Efficiency Score
WeakZJYL struggles to generate sufficient returns from assets.
Valuation Score
ExcellentZJYL trades at attractive valuation levels.
Growth Score
ExcellentZJYL delivers strong and consistent growth momentum.
Financial Health Score
ExcellentZJYL maintains a strong and stable balance sheet.
Profitability Score
WeakZJYL struggles to sustain strong margins.
Key Financial Metrics
Is ZJYL Expensive or Cheap?
P/E Ratio
ZJYL trades at 18.67 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, ZJYL's PEG of -0.56 indicates potential undervaluation.
Price to Book
The market values Jin Medical International Ltd. at 0.75 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 12.34 times EBITDA. This signals the market has high growth expectations.
How Well Does ZJYL Make Money?
Net Profit Margin
For every $100 in sales, Jin Medical International Ltd. keeps $5.76 as profit after all expenses.
Operating Margin
Core operations generate 2.94 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.14 in profit for every $100 of shareholder equity.
ROA
Jin Medical International Ltd. generates $2.23 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Jin Medical International Ltd. produces operating cash flow of $2.90M, showing steady but balanced cash generation.
Free Cash Flow
Jin Medical International Ltd. generates weak or negative free cash flow of $-3.73M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.02 in free cash annually.
FCF Yield
ZJYL converts -16.76% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
18.67
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.56
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.75
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.08
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.64
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.86
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How ZJYL Stacks Against Its Sector Peers
| Metric | ZJYL Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 18.67 | 29.43 | Better (Cheaper) |
| ROE | 4.14% | 800.00% | Weak |
| Net Margin | 5.76% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.64 | 0.30 | Weak (High Leverage) |
| Current Ratio | 1.86 | 4.64 | Neutral |
| ROA | 2.23% | -17936.00% (disorted) | Weak |
ZJYL outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Jin Medical International Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
195.07%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
157.70%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-132.91%
Industry Style: Defensive, Growth, Innovation
Declining